Omalizumab (Xolair)
Humanized IgG1 monoclonal antibody binding free IgE and preventing IgE-FceRI engagement on mast cells and basophils. Approved for moderate-to-severe persistent allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and food allergy. Asthma dosing by body weight and total serum IgE (75-375 mg SC every 2-4 weeks); CSU 150-300 mg monthly. Biphasic PK with terminal half-life ~26 days. SC bioavailability ~62%. Boxed warning: rare anaphylaxis post-administration.
Projected serum levels — 300 mg, custom (shown daily)
Maintenance schedule: 300 mg custom (shown daily) (subcutaneous).
Loading schedule: 900 mg on day 1, then 300 mg custom (shown daily) — reaching therapeutic levels sooner.
Modeled steady state after ~108 days: peak ≈ 7.6k mg, trough ≈ 7.6k mg body load. Population-based estimate over 121 days for a 300 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Biologic
- Route modeled
- Subcutaneous
- Model confidence
- inferred
- Half-life
- 26 days
- Common dose
- 300 mg
- Suggested maximum
- 375 mg/day
- Reference dose range
- 150–375 mg (single dose)
- Suggested cadence
- custom (shown daily)
Research behind this entry
-
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
Mechanistic PK/PD model quantifying omalizumab-IgE binding kinetics and disposition; supports dose-by-weight-and-IgE nomogram.
-
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma
Pivotal efficacy trial demonstrating reduced exacerbations and improved symptom control with omalizumab in severe allergic asthma.
2 published studies referenced in the app, each with a plain-language summary.